ArticleThe Journal of clinical endocrinology and metabolism2014
Vascular pool of releasable soluble VEGF receptor-1 (sFLT1) in women with previous preeclampsia and uncomplicated pregnancy.
Article in The Journal of clinical endocrinology and metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 21 citations in OpenAlex.
- Soluble fms-like tyrosine kinase-1 and placental growth factor as predictors of adverse maternal events in women with a confirmed diagnosis of preeclampsia.Pregnancy (Hoboken, N.J.) · 2026Article
- Genetic Variants Associated With Preeclampsia and Maternal Serum sFLT1 Levels.Hypertension (Dallas, Tex. : 1979) · 2025Article
- Pathological staging of chorioamnionitis contributes to complications in preterm infants.Italian journal of pediatrics · 2020Article
- Mechanisms of Endothelial Dysfunction in Pre-eclampsia and Gestational Diabetes Mellitus: Windows Into Future Cardiometabolic Health?Frontiers in endocrinology · 2020Review
- Intrauterine Inflammation Damages Placental Angiogenesis via Wnt5a-Flt1 Activation.Inflammation · 2019Article
- A Maternally Sequestered, Biopolymer-Stabilized Vascular Endothelial Growth Factor (VEGF) Chimera for Treatment of Preeclampsia.Journal of the American Heart Association · 2017Article
- Obstetric antiphospholipid syndrome: early variations of angiogenic factors are associated with adverse outcomes.Haematologica · 2017Observational
- Low Soluble Syndecan-1 Precedes Preeclampsia.PloS one · 2016Article
- Methodological differences account for inconsistencies in reported free VEGF concentrations in pregnant rats.American journal of physiology. Regulatory, integrative and comparative physiology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
contextResearch examining the source of excess soluble fms-like tyrosine kinase 1 (sFLT1) in preeclampsia has focused on the placenta. The potential contribution of the releasable store of sFLT1 in the systemic vasculature is unknown.
objectiveWe asked whether the nonplacental releasable store of sFLT1 is larger in women with previous preeclampsia than in women with a previous uncomplicated pregnancy.
designWe administered heparin to nulligravid women and to women with previous preeclampsia or a previous uncomplicated pregnancy. We compared post-heparin sFLT1 concentrations with those observed in uncomplicated pregnancy and preeclampsia.
settingThe study was performed at Magee-Womens Hospital. PATIENTS: Participants included nulligravidas (n = 8), women 6-24 months postpartum (previous uncomplicated pregnancy, n = 16; previous preeclampsia, n = 15), and pregnant women (uncomplicated pregnancy, n = 30; preeclampsia, n = 25).
interventionNonpregnant women received an unfractionated heparin bolus.
main outcome measuresPre- and post-heparin plasma sFLT1, placental growth factor, and vascular endothelial growth factor were measured.
resultsIn nonpregnant women, heparin increased plasma sFLT1 by 250-fold (P < .01), increased placental growth factor by 7-fold (P < .01), and decreased free vascular endothelial growth factor (P < .01). These changes did not differ between nulligravidas, women with previous preeclampsia, and women with a previous uncomplicated pregnancy. Post-heparin sFLT1 in nonpregnant women was higher than sFLT1 in uncomplicated pregnancy, but lower than sFLT1 in preeclampsia. Baseline and post-heparin sFLT1 were positively correlated (r(2) = 0.19; P < .01). Heparin increased the concentration of the 100-kDa sFLT1 isoform. Adding heparin to whole blood or plasma did not increase sFLT1.
conclusionsNonpregnant women have a significant vascular store of releasable sFLT1. The size of this store does not differ between women with previous preeclampsia vs women with previous uncomplicated pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.